The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2013
Filed:
Apr. 03, 2012
Klarisa Rikova, Reading, MA (US);
Herbert Haack, South Hamilton, MA (US);
Laura Sullivan, Shrewsbury, MA (US);
Ailan Guo, Lexington, MA (US);
Anthony Possemato, Worcester, MA (US);
Joan Macneill, Litchfield, NH (US);
Ting-lei Gu, Woburn, MA (US);
Jian Yu, Hamilton, MA (US);
Klarisa Rikova, Reading, MA (US);
Herbert Haack, South Hamilton, MA (US);
Laura Sullivan, Shrewsbury, MA (US);
Ailan Guo, Lexington, MA (US);
Anthony Possemato, Worcester, MA (US);
Joan MacNeill, Litchfield, NH (US);
Ting-Lei Gu, Woburn, MA (US);
Jian Yu, Hamilton, MA (US);
Cell Signaling Technology, Inc., Danvers, MA (US);
Abstract
Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.